Innovent Biologics Inc 1801.HK

Innovent Biologics, Inc. is based in China and is an investment holding company that engages in the biopharmaceutical industry. Through its subsidiaries, it develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, and cardiovascular diseases. Innovent Biologics, Inc. was founded in 2011 in Suzhou, China, and is primarily focused on local distribution and development.

The main product offerings of Innovent Biologics, Inc. cover a wide array of pharmaceuticals, including a PD-1 antibody for the treatment of cancer; bevacizumab (Avastin) biosimilar IBI-305 to treat types of colorectal and lung cancers; rituximab (MabThera/Rituxan) biosimilar IBI-301 to treat non-Hodgkin's lymphoma and chronic lymphocytic leukaemia; and adalimumab (Humira) biosimilar IBI-303 to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Its highest-profile drug candidates include treatments for a wide range of cancers, Hodgkin’s lymphoma, and oesophageal cancer. The company has developed strategic collaborations with the University of Texas MD Anderson Cancer Centre and Eli Lilly & Company.

Innovent Biologics, Inc. is publicly listed on the Hong Kong Stock Exchange, where it can be found under the ticker 1801.HK. It has traded on the exchange since October 2018.

Add 1801.HK stock to your eToro watchlist to keep an eye on the Innovent Biologics Inc. share price.